GLP-1类治疗与老年MASLD患者长期临床结局的回顾性队列研究
该回顾性队列研究基于TriNetX美国协作网络,纳入65岁及以上MASLD患者,经倾向评分匹配后比较GLP-1受体激动剂启用者与未暴露者。结果显示GLP-1 RA与肝失代偿、死亡和住院风险降低相关,MACE无显著减少,部分不良事件更常见。
要点
- 老年MASLD患者启用GLP-1 RA与肝失代偿风险降低相关(HR 0.72)。
- GLP-1 RA与死亡风险降低相关(HR 0.55),住院风险轻度降低(HR 0.95)。
- MACE未见显著减少(HR 0.98),需关注特定不良事件增加。
核心结论
- 在老年MASLD患者中,启用GLP-1 RA与肝失代偿、住院和死亡风险降低相关,但部分不良事件发生率更高。
研究设计与样本
- 回顾性队列研究,使用TriNetX美国协作网络,纳入65岁及以上MASLD成人,排除肝移植及其他肝病病因。
- 采用新使用者、意向性治疗设计,1:1倾向评分匹配,比较GLP-1 RA启用者与未暴露者。
主要发现
- GLP-1 RA与肝失代偿风险降低相关(HR 0.72,95%CI 0.66-0.79)。
- GLP-1 RA与死亡风险降低相关(HR 0.55,95%CI 0.52-0.58)。
- GLP-1 RA与住院风险轻度降低相关(HR 0.95,95%CI 0.93-0.97)。
- MACE未见显著减少(HR 0.98,95%CI 0.92-1.04)。
- 无骨折的骨质疏松和视网膜病变更常见;胰腺炎、肌少症和骨折无差异;胃肠道事件作为首次事件更常见。
临床怎么用
- 对老年MASLD患者,GLP-1 RA治疗可能与改善肝失代偿、住院和生存结局相关,但需权衡特定不良事件风险。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in older adults, driving hepatic decompensation and cardiovascular mortality. Randomised trial data on glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) therapy remain limited. METHODS: We conducted a retrospective cohort study using TriNetX US Collaborative Network. Adults 65 years or older with MASLD were identified by codes for fatty liver disease or steatohepatitis plus one cardiometabolic risk factor. We excluded liver transplant and other liver disease causes. Using a new-user, intention-to-treat design with 1:1 propensity-score matching, we compared GLP-1 RA initiators with unexposed patients. Outcomes were hepatic decompensation, hospitalisation, mortality and major adverse cardiovascular events (MACE), assessed 90 days to 10 years after index. Sensitivity analyses restricted follow-up to 1-10 years, excluded tirzepatide or began follow-up on day 1. FINDINGS: We identified 44 196 GLP-1 RA initiators and 384 672 unexposed patients. After matching, 43 930 remained per cohort (mean age 71.8 years; 62.0% female), with standardised mean differences below 0.1. GLP-1 RA use was linked to lower hazards of hepatic decompensation (hazard ratios [HR] 0.72, 95% confidence intervals [CI] 0.66-0.79), mortality (HR 0.55, 0.52-0.58) and hospitalisation (HR 0.95, 0.93-0.97). MACE showed no reduction (HR 0.98, 0.92-1.04). Osteoporosis without fracture and retinopathy were more frequent; pancreatitis, sarcopenia and fracture did not differ. GI events occurred more often as first events. Sensitivity analyses confirmed results for decompensation, hospitalisation and mortality. INTERPRETATION: In older adults with MASLD, GLP-1 RA initiation was linked to lower risks of hepatic decompensation, hospitalisation and mortality, with higher rates of selected adverse events.
引用
- Koutouratsas T, Kalligeros M, Michael M, et al. GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study. Age Ageing. 2026. PMID: 42765724. doi:10.1093/ageing/afag281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。